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Objectives: Arterial hypertension (AH) largely determines the high mortality rate 
and disability of working age persons from coronary heart diseases. In Ukraine 
in 2012 according to official statistics 12.1 million patients with AH were regis-
tered. It is 32.2% of the adult population. The purpose of the study - assessment 
structure and volume of antihypertensive drugs (AHDs) consumption during 2008-
2013 in Ukraine. MethOds: Analysis of AHDs consumption was performed using 
ATC/DDD-methodology and data of drugs supply in informational-search system 
“Pharmaceuticals” of company MORION during 2008-2013. Consumption of AHDs 
was determined in the indicator: DDDs / 1000 inhabitans / day (DIDs). AHDs of the 
first-line: thiazide and thiazide-type diuretics, β -blockers, calcium channel block-
ers, ACE inhibitors, angiotensin II receptor blockers and the second line: α -block-
ers, central antiadrenergic drugs, peripheral vasodilators were analyzed. Results: 
Volume of AHDs consumption increased from 60,64 DIDs in 2008 to 96,43 DIDs in 
2013. About 6.08% - 9.6% of inhabitans take one DDD per day. Recalculation vol-
umes of AHDs consumption for a total aggregate of patients with AH showed that 
only 23% - 36% of patients receive treatment. This testifies to the low adherence of 
patients to treatment. A comparison the volumes of AHDs consumption has shown 
that the consumption of AHDs in Ukraine is less, but stroke mortality is higher than 
in the developed countries. Consumption of AHDs of the first line accounts for a 
large share which increased from 83.7% in 2008 to 89.3% in 2013. Consumption of 
AHDs of the second line decreased. cOnclusiOns: Structure of AHDs consump-
tion in Ukraine indicates compliance of antihypertensive therapy to current clinical 
guidelines. The consumption of AHDs in Ukraine is less than in other countries, 
so the most urgent problem for Ukraine is to find mechanisms for increasing the 
adherence of patients to hypertension treatment.
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Objectives: To assess in a community setting how patients discharged alive after 
an ACS are treated with statins. Specifically, the rate of prescription, the dosages and 
1-year adherence have been evaluated. MethOds: From the ARNO Observatory, we 
carried out a record linkage analysis of discharge records for ACS and prescription 
databases, which included 2,989,512 subjects of 7 Local Health Authorities from 
Northern to Southern Italy. The accrual period lasted from January 1 to December 
31, 2011. Results: Of the 2,989,512 subjects, 6,226 (2.1‰) were hospitalized for ACS 
over the 12 months of observation, 58% of patients were aged more than 70 years, 
females accounted for 36% of the cases, diabetes was reported in 31%. In-hospital 
all-cause death was 4.6%. Of the patients discharged alive, 69.9% received a statin 
treatment at the time of discharge. High dosage of statins were used in 70.4% of 
cases. After 1 year follow-up, adherence to treatment was observed in 71.7% of 
patients. Over the 1-year follow-up, 63.3% of the patients needed to be readmit-
ted again (50.4% for cardiovascular causes). The average yearly cost per patient for 
the total ACS population was 16,897€ /year (drugs, 1,692€ ; hospitalizations, 14,198€ ; 
diagnostic and outpatient visits, 1,007€ ). cOnclusiOns: In a community setting, 
the rate of prescription of statins after an ACS seems to be at least suboptimal. 
However, the dosages of prescribed statins suggest that the use of intensive statin 
treatment increased over the last few years. Prescription continuity over time was 
not adequately followed. Patients with ACS have high direct healthcare costs, rehos-
pitalization being the main cost driver. There is still a gap between evidence based 
recommendations and what actually happens in the routine clinical practice, surely 
determining a high social and economical burden for the national health structures.
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Objectives: Despite the availability of effective prophylactic and therapeutic 
options, VTE continues to be under diagnosed and undertreated. The incidence of 
DVT in India, however, is comparable to that in the Western countries. This study 
aimed to assess the adherence of treatment guidelines in the prophylaxis of DVT 
and evaluated the risk factors associated with DVT. MethOds: The prospective 
study was carried out at an Indian tertiary healthcare setting where the patients 
were enrolled in the study as per the defined inclusion and exclusion criteria. The 
results are based on findings from a total of 230 patients. The patients were clas-
sified into four different categories based on the risk of DVT- low, moderate, high 
and highest. Results: The results are based on data obtained from 158 female 
and 72 male patients. The average age of the patients was found to be 62.1±0.9 
yrs. The average age of female patients was found to be statistically significantly 
higher than the average age of male patients. Of 230 patients, 207 patients received 
Enoxaparin/ Rivaroxaban/ Diateparin for prophylaxis and 5 patients through DVT 
pump and limb physiotherapy. It was found that 18 patients did not receive any type 
of DVT prophylaxis; and, out of 18 patients, 10 were managed for DVT prophylaxis 
with active toe movements. The adherence to the pharmacological prophylaxis 
was found to be 92.2%. cOnclusiOns: The results of this study have shown that 
the adherence to ACCP guidelines in DVT prophylaxis in this study population was 
high (92.2%). Further, an association between surgery (major surgery, orthopaedical 
surgery), age and DVT risk appears to be existent.
Objectives: Clinical trials comparing rivaroxaban or dabigatran to warfarin 
show similar results for major and non-major clinically relevant bleeding. Post-
marketing data regarding bleeding rates for these new oral anticoagulants (NOACs) 
is lacking. Our goal was to evaluate bleeding related outcomes with NOACs using 
a disproportionality analysis of spontaneous adverse event reports. MethOds: 
We evaluated the FAERS database from 10/2011 – 12/2012 to compare frequency 
of events in reports of rivaroxaban, dabigatran, and warfarin related to fatal and 
non-fatal bleeding. Reports were included if the anticoagulant was the primary 
suspected agent for the event. Reporting odds ratio (ROR) and proportional report-
ing ratio (PRR) were calculated to estimate risk for each anticoagulant. Results: 
Of 22,244 eligible adverse drug reports for the anticoagulants, 7661 (34%) bleed-
ing reports were submitted, with 1868 (24%) deaths, 5028 (66%) hospitalizations 
and 1040 (14%) life-threatening events. Dabigatran was the most commonly 
reported anticoagulant exposure among bleeding cases (n= 5203, 68%). Of the 
bleeding cases associated with dabigatran, death was reported in 29%, hospi-
talization in 67%, and life-threatening events in 15% of cases. The odds of expo-
sure for fatal bleeding was significantly higher with dabigatran (ROR 2.28, 95% 
confidence interval [CI] 2.02-2.56) and significantly lower with rivaroxaban (ROR 
0.75, CI = 0.69-0.8) and warfarin (ROR 0.53, CI = 0.44-0.63). PRR indicated sig-
nificantly increased risk of non-fatal bleeding with dabigatran (PRR = 2.12, CI 
= 1.99-2.24) and warfarin (PRR = 1.27, CI = 1.17-1.38) with a significant decrease 
associated with rivaroxaban (PRR 0.8, CI = 0.75-0.86). cOnclusiOns: Among the 
NOACs, patients having fatal and non-fatal bleeding were found to have higher 
odds of dabigatran exposure and significantly lower odds of rivaroxaban expo-
sure. Though FAERS is subject to significant bias, the results suggest dabigatran-
related bleeding is higher in clinical practice and rivaroxaban may be a safer 
alternative.
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Objectives: Arterial hypertension represents a major cause of morbidity and 
mortality among elderly population in Novi Sad, Serbia. The aim of this study 
was to analyze patterns and address financial aspects of antihypertensive drug 
utilization among elderly outpatients (> 60). MethOds: Data on antihypertensive 
issued on prescription were collected from all state-owned pharmacies in Novi Sad 
(population 350,000) from September 2011 to February 2012. Consumption was cal-
culated using the ATC/DDD methodology, and results were expressed in DDD/1000 
inhabitants/day. DU90% (drug utilization 90%) segment and price per DDD were 
determined. Results: The total use of antihypertensives among population > 60 
years in Novi Sad, Serbia was 203.1 DDD/1000inh/day. ACE inhibitors were the most 
frequently used drugs and accounted for 58.44% of total consumption, followed 
by calcium channel blockers (23.51%) and beta-blockers (11.10%). Consumption of 
diuretics (4.29%) and angiotensin receptor antagonists (< 3%) was low. High use of 
ACE inhibitors was also reflected in DU90% profile. Even though most commonly 
prescribed drug was amlodipine (18.49%), out of 16 drugs within DU90% segment, 
10 were ACE inhibitors or ACE inhibitors/diuretics fixed combinations. Average 
price per DDD within DU90% was 0.09 euro per DDD whereas it was 0.12 euro 
per DDD for drugs beyond the DU90% segment. cOnclusiOns: High consump-
tion of ACE inhibitors and disregard to other antihypertensive agents points to 
therapeutic irrationalities which can have considerable clinical and economic 
consequences. Targeted education may both improve efficacy of treatment of 
hypertension in elderly and provide significant savings. Acknowledgement: This 
work was supported by the Ministry of Science and Technological Development, 
Republic of Serbia, project No. 41012.
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Objectives: Anxiety and depression are prevalent in individuals with coronary 
heart disease. Selective-serotonin reuptake inhibitors (SSRI) are first-line therapy 
for many anxiety and depression disorders. Platelet aggregation inhibitors (PAI) 
are the cornerstone of therapy for various types of heart disease. These medi-
cations are relatively contraindicated due to an increased risk for many types 
of bleeding. The purpose of the study was to examine the prevalence and pre-
dictors of use of both SSRI and PAI among individuals with co-occurring heart 
disease and anxiety or depression. MethOds: Respondents who were age 22 
years and older, alive throughout the study period, diagnosed with heart dis-
ease and co-occurring anxiety or depression (n= 1,253) in 2009-11 of the Medical 
Expenditures Panel Survey were included. Use of treatment was grouped as: 1) 
SSRI and PAI, 2) SSRI or PAI, and 3) Neither SSRI or PAI. Results: Overall, 11.2% 
used both SSRI and PAI, 46.3% used SSRI or PAI, and 42.5% used neither SSRI 
nor PAI. Significant subgroup differences were observed in the use of treat-
ment. Females were less likely to be prescribed the inappropriate combination 
[AOR 0.57 (95%CI= 0.36-0.92)] while respondents having education less than 
high school [AOR 2.27 (95%CI= 1.30-3.99)] or a diagnosis of diabetes [AOR 2.13 
(95%CI= 1.28-3.53)] were more likely to be prescribed the inappropriate combina-
tion. cOnclusiOns: In this sample potentially inappropriate medication use 
was prevalent. Patients with less education or lower socioeconomic status are 
more likely to have health disparities and are at higher risk for both physical and 
mental health conditions. In this study, the patients with lower levels of education 
were more likely to be receiving an inappropriate combination of medications. 
The strong association with diabetes diagnosis and treatment choice is important 
because of the increased risk for bleeding in patients who received treatment for 
diabetes.
